施普善治疗创伤性颅脑损伤（TBI）临床疗效的初步观察
发布时间：2019-04-24 17:19
【摘要】：目的 该实验的目的是探讨GCS评分为（7-12）分的创伤性颅脑损伤患者，将施普善作为标准治疗方案的追加治疗后，观察其在治疗期、康复期及远期三个时期的临床效果。 研究对象与方法 2010年2月-2012年9月期间，在泰山医学院附属医院神经外科收治的GCS评分为（7-12）分范围内的创伤性颅脑损伤（TBI）患者，共60例。将60例TBI患者按照随机分配原则分为实验组（35例）和对照组（25例）。实验组和对照组的患者除按照颅脑损伤救治指南的标准治疗方案进行治疗外，实验组还追加相同剂量(见表1)施普善药物治疗。两组都从入院治疗后第30天、第90天及180天三个时期，从简易精神状态检查（MMSE）、处理速度指数（PSI）（WALS-第三版）、远期生活质量评估三个方面来评价施普善药物在创伤性颅脑损伤（TBI）患者中的疗效。在治疗期间根据副反应量表(DOTES和TWIS)记录的不良事件以及3个月时的死亡率作为安全性指标评定本药物的安全性。用SPSS13.0统计软件进行统计学分析，计量资料用x s表示，组间比较行t检验，以p0.05为差异有统计学意义。 结果 ①符合入组条件患者为60例，因故中途退出研究者7例，因此共有53例样本纳入本研究结果。 ②通过对实验组和对照组两组间比较，在治疗后的第30天、第90天和第180天三个时期对患者行MMSE、PSI和远期生活质量三个指标进行测试；对照组和实验组在治疗的第30天、第90天及180天比较分析均有差异性（P＜0.05），且具有统计学意义。特别是在远期生活质量方面，第180天时，实验组平均分为（4.74±0.51），对照组平均分为（4.09±0.43），两组相比具有明显差异性。 ③治疗3个月共死亡患者7例，死因均为肺部感染。实验组死亡患者4例，占11.4%；对照组死亡患者3例，占12%，，两组间死亡率比较无明显差异性。 结论 施普善(Cerebrolysin,脑活素)在作为追加治疗的GCS评分为（7-12）分的创伤性颅脑损伤患者中，在治疗后的第30天、第90天及180天均能明显提高患者在MMSE、PSI和远期生活质量三个指标中的评分，对患者的远期生活质量效果尤为显著，经过初步验证施普善是一种有效、安全的药物。对创伤性颅脑损伤患者的临床治疗提供了一种可靠的临床治疗方案。
[Abstract]:Objective the purpose of this experiment was to investigate the traumatic brain injury patients whose GCS score was (7? 12), and to observe the therapeutic period of Spusanne as a standard treatment regimen. Clinical effects of convalescence and long-term period. Participants and methods from February 2010 to September 2012, 60 patients with traumatic craniocerebral injury (TBI) were enrolled in the neurosurgery department of the affiliated Hospital of Taishan Medical College. Sixty patients with TBI were divided into experimental group (n = 35) and control group (n = 25) according to the principle of random distribution. The patients in the experimental group and the control group were treated with the same dosage (see Table 1) in addition to the standard treatment plan in the treatment guidelines for craniocerebral injury (see Table 1). From the 30th, 90th and 180th days after admission, the (MMSE), processing velocity index (PSI) (WALS- 3rd edition) was measured from the mini-mental state examination in both groups. Long-term assessment of quality of life (QOL) was used to evaluate the efficacy of Spusa in traumatic craniocerebral injury (TBI) patients. The safety of the drug was evaluated according to adverse events recorded by DOTES and TWIS during treatment and mortality at 3 months. SPSS13.0 statistical software was used for statistical analysis. The measurement data were expressed by x / s. T-test was used to compare the data between groups, and the difference was statistically significant with p0.05 as the difference. Results (1) 60 patients met the criteria of admission and 7 patients dropped out of the study. Therefore, 53 samples were included in this study. (2) MMSE,PSI and long-term quality of life (QOL) were measured on the 30th day, 90th day and 180th day after treatment between the experimental group and the control group. There was significant difference between the control group and the experimental group on the 30th, 90th and 180th day of treatment (P < 0.05). On the 180th day, the average score of the experimental group was (4.74 卤0.51), that of the control group was (4.09 卤0.43), there was significant difference between the two groups. 3There were 7 cases of death after 3 months treatment, all the causes of death were pulmonary infection. There were 4 dead patients (11.4%) in the experimental group and 3 dead patients (12%) in the control group. There was no significant difference in the mortality between the two groups. Conclusion in the patients with traumatic craniocerebral injury (TBI) whose GCS score (7? 12) as supplementary treatment, Cerebrolysin, can significantly improve the level of MMSE, on the 30th, 90th and 180th day after the treatment. [WT5 "HZ] conclusion [WT5" BZ] [WT5 "BZ] The score of PSI and long-term quality of life (QOL) is especially significant for the patients with long-term quality of life. It has been preliminarily proved that Spusanne is an effective and safe drug. It provides a reliable clinical treatment for traumatic craniocerebral injury patients.
【学位授予单位】：泰山医学院
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R651.15
[Abstract]:Objective the purpose of this experiment was to investigate the traumatic brain injury patients whose GCS score was (7? 12), and to observe the therapeutic period of Spusanne as a standard treatment regimen. Clinical effects of convalescence and long-term period. Participants and methods from February 2010 to September 2012, 60 patients with traumatic craniocerebral injury (TBI) were enrolled in the neurosurgery department of the affiliated Hospital of Taishan Medical College. Sixty patients with TBI were divided into experimental group (n = 35) and control group (n = 25) according to the principle of random distribution. The patients in the experimental group and the control group were treated with the same dosage (see Table 1) in addition to the standard treatment plan in the treatment guidelines for craniocerebral injury (see Table 1). From the 30th, 90th and 180th days after admission, the (MMSE), processing velocity index (PSI) (WALS- 3rd edition) was measured from the mini-mental state examination in both groups. Long-term assessment of quality of life (QOL) was used to evaluate the efficacy of Spusa in traumatic craniocerebral injury (TBI) patients. The safety of the drug was evaluated according to adverse events recorded by DOTES and TWIS during treatment and mortality at 3 months. SPSS13.0 statistical software was used for statistical analysis. The measurement data were expressed by x / s. T-test was used to compare the data between groups, and the difference was statistically significant with p0.05 as the difference. Results (1) 60 patients met the criteria of admission and 7 patients dropped out of the study. Therefore, 53 samples were included in this study. (2) MMSE,PSI and long-term quality of life (QOL) were measured on the 30th day, 90th day and 180th day after treatment between the experimental group and the control group. There was significant difference between the control group and the experimental group on the 30th, 90th and 180th day of treatment (P < 0.05). On the 180th day, the average score of the experimental group was (4.74 卤0.51), that of the control group was (4.09 卤0.43), there was significant difference between the two groups. 3There were 7 cases of death after 3 months treatment, all the causes of death were pulmonary infection. There were 4 dead patients (11.4%) in the experimental group and 3 dead patients (12%) in the control group. There was no significant difference in the mortality between the two groups. Conclusion in the patients with traumatic craniocerebral injury (TBI) whose GCS score (7? 12) as supplementary treatment, Cerebrolysin, can significantly improve the level of MMSE, on the 30th, 90th and 180th day after the treatment. [WT5 "HZ] conclusion [WT5" BZ] [WT5 "BZ] The score of PSI and long-term quality of life (QOL) is especially significant for the patients with long-term quality of life. It has been preliminarily proved that Spusanne is an effective and safe drug. It provides a reliable clinical treatment for traumatic craniocerebral injury patients.
【学位授予单位】：泰山医学院
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R651.15
【参考文献】
相关期刊论文 前5条
1 刘卫平,章翔,易声禹,方宏,费舟,付洛安,程光,顾建文;大鼠急性颅脑损伤后脑微循环的变化[J];第四军医大学学报;2000年12期
2 高峰;崔o
本文编号：2464635
本文链接：https://www.wllwen.com/yixuelunwen/jjyx/2464635.html
最近更新
教材专著
